Last Updated : May 18, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area Sort ascending | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Blincyto | Blinatumomab | Acute Lymphoblastic Leukemia | Reimburse with clinical criteria and/or conditions | Complete | ||
| Rituxan | Rituximab | Acute Lymphoblastic Leukemia | Do not reimburse | Complete | ||
| Rylaze | crisantaspase recombinant | Acute lymphoblastic leukemia | Reimburse with clinical criteria and/or conditions | Complete | ||
| Givlaari | givosiran | Acute hepatic porphyria (AHP) in adults | Reimburse with clinical criteria and/or conditions | Complete | ||
| Brilinta | Ticagrelor | Acute Coronary Syndromes | Cancelled | |||
| Brilinta | Ticagrelor | Acute coronary syndromes | Do not list | Complete | ||
| Effient | Prasugrel | Acute coronary syndrome | Do not list | Complete | ||
| Effient | Prasugrel hydrochloride | Acute Coronary Syndrome | Do not list | Complete | ||
| Sivextro | Tedizolid phosphate | Acute bacterial skin and skin structure infections | Withdrawn | |||
| Xydalba | dalbavancin | Acute bacterial skin and skin structure infections | Reimburse with clinical criteria and/or conditions | Complete |
Last Updated : May 18, 2024